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Background. Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP)
intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pregnant women is unknown. We examined
effectiveness of CTX with or without SP-IPTp versus SP-IPTp at reducing malaria parasitemia and anemia.
Methods. From 2005 to 2009, we conducted a cross-sectional study of HIV-infected pregnant women at Thyolo
Hospital, Malawi. Blood was tested for malaria parasitemia and anemia (hemoglobin,11g/dl). Data were collected on
useofanti-malariainterventionsandotherriskfactors.CTXprophylaxispolicyforHIV-infectedpregnantwomenwas
introduced in 2007, but implementation problems resulted in some women receiving both CTX and SP-IPTp.
Findings. We enrolled 1,142 women, of whom 1,121 had data on CTX and/or SP-IPTp intake. Of these, 49.7%,
29.8%, and 15.4% reported taking SP-IPTp only, CTX only and SP-IPTp plus CTX, respectively. Compared with
women taking SP-IPTp, those taking SP-IPTp plus CTX and CTX were less likely to have malaria parasitemia (OR,
[95%CI]: 0.09, [0.01-0.66] and 0.43, [0.19-0.97], respectively) or anemia (PR, [95% CI]: 0.67, [0.54-0.83] and 0.72,
[0.61-0.83], respectively).
Conclusion. In HIV-infected pregnant women, daily CTX was associated with reduced malaria parasitemia
and anemia compared with SP-IPTp. CTX plus SP-IPTp was associated with further reduction in malaria
parasitemia but toxicity was not fully assessed.
Malaria in pregnancy is a preventable cause of signiﬁ-
cant maternal and perinatal morbidity and mortality in
sub-Saharan Africa [1]. Human immunodeﬁciency vi-
rus (HIV) infection increases the risks of placental and
peripheral malaria, high-density parasitemia, and febrile
malaria illness among pregnant women [2–5]. HIV-
infected pregnant women are at an increased risk of
premature delivery, severe anemia, delivery of low-
birth-weight infants, and maternal death as a result of
frequent and severe malaria infections [5].
In countries where malaria is endemic, women re-
ceive sulfadoxine-pyrimethamine (SP) intermittent
preventive therapy during pregnancy (IPTp) to prevent
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zation (WHO) currently recommends that HIV-infected preg-
nant women receiving daily trimethoprim-sulfamethoxazole
(TMP-SMX) prophylaxis should not be given as SP-IPTp, to
avoid adverse drug reactions associated with sulfa drug toxicity
[7]. Countries such as Uganda and Malawi currently recom-
mend daily TMP-SMX to all HIV-infected pregnant women to
prevent opportunistic infections [8]. However, these recom-
mendations are not based on empirical evidence [9, 10]. Al-
though TMP-SMX has been shown to decrease malaria
morbidity in children and HIV-infected adults [11–14], its ef-
ﬁcacy, safety, and effectiveness to prevent malaria have not been
evaluated in HIV-infected pregnant women [15]. No study has
assessed the effects of daily TMP-SMX prophylaxis, compared
with SP-IPTp, in HIV-infected pregnant women.
We analyzed data from a cross-sectional study that was
conducted to investigate the effects of iron supplementation on
maternal morbidities. We compared the prevalence of malaria
parasitemia and anemia in HIV-infected pregnant women tak-
ing daily TMP-SMX, with or without SP-IPTp, with the prev-
alence in those taking SP-IPTp only.
METHODS
Study Site
The study was conducted from December 2005 through July
2009 in the antenatal clinic at Thyolo District Hospital in
southern Malawi. The hospital provides free antenatal services
and has a well-established program for prevention of mother-to-
childtransmission ofHIV infection(PMTCT). Measurementsof
CD4 T cell count and WHO HIV clinical staging are performed
on all women found to be HIV infected. HIV-infected pregnant
women classiﬁed in WHO HIV stage 3 or 4 or those with a CD4
cell count ,250 cells/lL received combination antiretroviral
therapy (ART) containing stavudine (30–40 mg), lamivudine
(150 mg), and nevirapine (200 mg) twice daily as a ﬁxed-dose
combination (Triomune) [16]. Those not eligible for ART re-
ceived single-dose nevirapine for PMTCT, in accordance with
the HIVNET 012 protocol. However, in 2007, these women
started receiving 300 mg zidovudine twice daily. Before 2007,
women with a CD4 cell count ,500 cells/lL or those classiﬁed
as WHO HIV stage 2, 3, or 4 were eligible for TMP-SMX pro-
phylaxis [17]. In line with the Malawi Ministry of Health rec-
ommendations, TMP-SMX prophylaxis (480 mg twice daily) to
all HIV-infected pregnant women for the prevention of oppor-
tunistic infections was introduced at the hospital in 2007.
However, confusion about the exact implementation of this
policy resulted in some women receiving SP-IPTp only and
othersreceiving acombination ofdailyTMP-SMX andSP-IPTp.
Study Population, Enrollment, and Data Collection
We used data from a cross-sectional study investigating the
effects of routine iron supplementation in HIV-infected
pregnant women on maternal morbidities. The study included
HIV-infected pregnant women aged >15 years and with ges-
tation >34 weeks who were attending routine antenatal serv-
ices at the hospital. Women with immediate life-threatening
medical and obstetric conditions were excluded.
A study nurse administered a standardized questionnaire to
collect data that included sociodemographic and medical in-
formation; intake of medications, such as ART, SP-IPTp, TMP-
SMX, and iron supplements; and the use of bed nets. Physical
medical examination was also performed, which included
measurement of temperature, blood pressure, mid-upper arm
circumference (MUAC), weight, and height. Thereafter, pe-
ripheral venous blood samples were collected for thick blood
smear malaria microscopy and, later, for malaria DNA detection
using real-time polymerase chain reaction (PCR). The study was
approved by the Malawi College of Medicine Research and
Ethics Committee and by the institutional review board of the
University of North Carolina at Chapel Hill. All women pro-
vided informed consent before enrollment.
Laboratory Tests
Thick blood smears were stained with Field stains A and B [18].
Using light microscopy, 2 independent laboratory technicians
examined the stained smears to detect asexual forms of Plas-
modium falciparum malaria parasites. In case of discrepancy of
results, an experienced microscopist reread the slides, as a tie-
breaker. Malaria parasites were counted against 200 leukocytes.
To estimate the parasite density per microliter of blood, the
number of parasites counted was multiplied by 40 under the
assumption of leukocyte count of 8000 cells/lL of blood.
A blood ﬁlm result was considered to be negative if no parasites
were detected per 200 leukocytes.
To increase the detection of malaria infection, we also con-
ductedreal-timePCRformalariaparasiteDNAattheUniversity
of North Carolina at Chapel Hill (UNC-CH). DNA was ex-
tracted from dried ﬁlter paper using an invitrogen PureLink
Genomic DNA kit (Invitrogen) according to manufacturer’s
instructions.PCRampliﬁcationofthemalariaparasiteDNAwas
done in 2 steps using a pooling method as described in Taylor
et al [19]. CD4 T cell count measurement was performed using
Partec CyFlow counter (Partec GmbH). Hemoglobin concen-
tration measurement was performed for whole blood samples
with use of a Hemocue hemoglobinometer (HemoCue AB).
Definitions
Microscopic malaria infection was deﬁned as presence of malaria
parasites on microscopy; PCR-detected malaria infection was de-
ﬁned as positive result of PCR for malaria regardless of micros-
copy results. Anemia was deﬁned as hemoglobin concentration
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classiﬁed into 4 groups of antimalarial drug exposure based on
reported information veriﬁed by antenatal records: (1) SP-IPTp
Reduced Malaria with Cotrimoxazole in HIV1 Pregnant Women d JID 2011:203 (15 February) d 465plus TMP-SMX, (2) TMP-SMX only, (3) SP-IPTp only, and (4)
none (neither SP-IPTp nor TMP-SMX).
Statistical Analysis
Data were analyzed using SAS software, version 9.1 (SAS In-
stitute). In bivariate analyses, we used analysis of variance or
Student’s t test to compare differences among outcomes or ex-
posure and continuous variables that were normally distributed
variables. We used the Kruskal–Wallis test or Wilcoxon rank sum
test for continuous variables that were not normally distributed
variables, and the Pearson v
2 test for categorical variables.
We evaluated effect measure modiﬁcation with use of the
likelihood ratio test of the interaction term. We used directed
acyclic graphs to identify potential confounders for the associ-
ation of antimalarial drug exposure with malaria infection or
maternal anemia [20, 21]. A backward elimination strategy was
applied to select the best model using the criterion of >10%
absolute change in estimate. Variables that were assessed for
confounding and effect measure modiﬁcation included age
(,27 y or >27 years), gravidity (primigravidae, secondi-
gravidae, or multigravidae), number of antenatal visits, CD4 cell
count (,200, 200–499, or >500 cells/lL), body mass index, and
socioeconomic status (poor, middle, or high). Socioeconomic
status was obtained by calculating the wealth index with use of
the method described in Gwatkin et al [22, 23].
Logistic regression was used in the analysis of the association
between antimalarial drug exposure and malaria infection. We
used log-binomial regression [24–26] and linear regression in
the analysis oftheassociationofantimalarialdrugexposure with
anemia and hemoglobin concentration, respectively. We used
a Poisson regression model with robust variance estimator to
conﬁrm estimates from log-binomial regression [24, 27].
Because SP-IPTp has been the standard of care for malaria
prevention during pregnancy, the SP-IPTp group was used as
a referent.
RESULTS
Study Population
From December 2005 through July 2009, 1142 HIV-infected
pregnant women were enrolled. Of the women with available
data, 71 (6.2%) of 1141 were primigravidae and 1034 (90.8%) of
1139 were married. Participants had a median age of 27 years
(range, 16–46 years) and median CD4 cell count of 423 cells/lL
(range, 11–1528 cells/lL). Use of bed nets was reported by 675
(59.6%) of 1133 of the women, and 554 (48.5%) of 1142 of the
women reported taking ART.
Antimalarial Drug Exposure
Data on the use of SP-IPTp and TMP-SMX were available for
1121 (98.2%) of 1142 of the enrolled women. Among these par-
ticipants, 557 (49.7%) reported taking SP-IPTp only, 334 (29.8%)
TMP-SMX only, and 173 (15.4%) TMP-SMXSP-IPTp plus
TMP-SMX. Only 57 (5.1%) reported taking none of the drugs.
The groups were similar in terms of HIV disease clinical stage,
CD4 count, SES, and marital status (Table 1). However, women in
the SP-IPTp-only group were signiﬁcantly younger, less likely to
use bed nets, more likely to be primigravidae, and less likely to
report taking antiretroviral drugs compared with women in TMP-
SMX or TMP-SMX plus SP-IPTp groups (Table 1).
Prevalence of Malaria parasitemia and Anemia
Blood smear microscopy and real-time PCR results were avail-
able for 1114 (97.5%) of 1142 and 1128 (98.8%) of 1142 of
women, respectively. The prevalence of PCR-detected malaria
infection was almost 2 times higher (10.0% [113 of 1128]) than
that of microscopic malaria (5.5% [61 of 1114]). All PCR-pos-
itive malaria infections were due to P. falciparum among those
that had information on parasite species (n 5 70). However,
4.3% (3/70) had P. falciparum and P. malariae mixed infections,
whereas 1 (1.4%) of 70 had P. falciparum and P. ovale. Data on
hemoglobin concentration were available for 1140 (99.8%) of
1142 of the women. The prevalence of any anemia and moder-
ate-to-severe anemia (hemoglobin concentration, ,8g / d L )
were 45.1% (514 of 1140) and 1.6% (18 of 1140), respectively.
Associations Between TMP-SMX or SP-IPTp and Malaria
parasitemia
The prevalence of microscopic and PCR-detected malaria in-
fection was signiﬁcantly lower in women reporting taking TMP-
SMX plus SP-IPTp (.6% and 3.6%) and TMP-SMX only (2.7%
and 5.5%) than in those reporting taking SP-IPTp only (7.7%
and 13.5%) (Figure 1). The prevalence of microscopic malaria
infection and PCR-detected malaria infection tended to be
higher in womenwho reportednot taking TMP-SMX or SP-IPT
(14.0% and 19.6%) than those reporting taking SP-IPTp only,
but the difference was not statistically signiﬁcant (Table 2).
After adjusting for age, gravidity, number of antenatal visits,
CD4 cell count, bed net use and SES, the odds of microscopic
malaria infection were signiﬁcantly lower in women reporting
taking TMP-SMX plus SP-IPTp (adjusted OR, .09; 95% CI, .01–
.66) or TMP-SMX (adjusted OR, .43; 95% CI, .19–.97) than in
women who reported taking SP-IPTp only (Table 2). Likewise,
after adjusting for same variables above, the odds of PCR-
detected malaria infection were signiﬁcantly lower in women
who reported taking TMP-SMX plus SP-IPTp (adjusted OR,
.24; 95% CI, .10–.62) or TMP-SMX only (adjusted OR, .44; 95%
CI, .25–.78) than women who reported taking SP-IPTp only
(Table 2). The odds of microscopic malaria infection were
higher in women who reported not taking TMP-SMX or SP-
IPTp compared with those who reported taking SP-IPTp only
(adjusted OR, 1.84; 95% CI, .87–4.41) but this was not statis-
tically different (Table 2). The odds of microscopic malaria in-
fection or PCR-detected malaria infection were not statistically
different in women who reported taking TMP-SMX plus SP-
IPTp (adjusted OR, .21; 95% CI, .03–1.67) compared with
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95% CI, .20–1.56). We also observed that the prevalence of
microscopic and PCR-detected malaria infection were lower in
women who had taken TMP-SMX for >30 d than in women
who took TMP-SMX for ,30 d (v
2 test, 1.2% versus 6.7% and
4.0% versus 9.6% P 5 .002 and P 5 .041, respectively).
Associations of TMP-SMX or SP-IPTp With Anemia and
Hemoglobin Concentration
The prevalence of anemia was signiﬁcantly lower in women who
reportedtaking TMP-SMX plusSP-IPTp(34.7%) or TMP-SMX
only (35.6%) than in women who reported taking SP-IPTp only
(52.4%) (Table 3). After adjusting for age, gravidity, number of
antenatalvisits,CD4count,andBMI,theprevalenceofmaternal
anemia remained signiﬁcantly lower in women who reported
taking TMP-SMX plus SP-IPTp (adjusted prevalence ratio
[APR], .67; 95% CI, .54–.83) or TMP-SMX only (APR, .72; 95%
CI, .61–.83) than in women who reported taking SP-IPTp only.
Similarly, the mean hemoglobin concentration was signiﬁ-
cantly higher in women who reported taking TMP-SMX plus
SP-IPTp (mean hemoglobin concentration [standard deviation
(SD)], 11.4 [1.33] g/dL; P , .0001) or TMP-SMX only (mean
hemoglobin concentration [SD], 11.4 [1.36] g/dL; P , .0001)
than in women who reported taking SP-IPTp only (mean he-
moglobin concentration [SD], 10.8 [1.35] g/dL) (Table 3). After
adjusting for age, gravidity, number of antenatal visits, CD4
count, and BMI, the mean hemoglobin concentration remained
signiﬁcantly higher in women who reported taking TMP-SMX
plus SP-IPTp (adjusted difference in hemoglobin concentration
means, .52; 95% CI, .29–.75) or TMP-SMX only (adjusted dif-
ference in hemoglobin concentration means, .46; 95% CI, .27–
.64). Compared with women who took TMP-SMX for .60 d,
women who took TMP-SMX for ,30 d had lower hemoglobin
concentration (adjusted difference in hemoglobin concentration
means, 2.44; 95% CI, 2.80 to 2.07; P 5 .02) (Table 3). We
Table 1. Characteristics of HIV-infected pregnant women according to sulfadoxine-pyrimethamine intermittent preventive therapy
during pregnancy and cotrimoxazoleTMP-SMX intake at Thyolo District Hospital antenatal clinic, Malawi (2005–2009)
Characteristic
Drug Group
SP & TMP-SMX (n 5 173) TMP-SMX only (n 5 334) SP only (n 5 557) None (n 5 57) P Value
Age, median (range), y 28 (18–40) 27 (16–46) 26 (16–45) 27 (16–37) ,.0001
§
Gravidity, median (range) 4 (1–9) 4 (1–9) 3 (1–11) 3 (1–7) .002
§
Primigravidae, n (%) 8 (4.6) 16 (4.8) 44 (7.9) 2 (3.5)
Secundigravidae, n (%) 25 (14.5) 42 (12.6) 112 (20.1) 20 (35.1) .0001
c
ANC visits, median (range) 3 (1–5) 3 (1–8) 3 (1–8) 2 (1–4) .0001
§
,3 visits, n (%) 40 (23.1) 116 (34.8) 236 (42.4) 44 (77.2) ,.0001
c
Any bed net use*
Yes, n (%) 110 (63.6) 264 (79.5) 271 (49.2) 24 (42.1) .001
c
CD4 cell count (cells/lL)
,200, n (%) 19 (11.0) 25 (7.5) 65 (11.7) 5 (8.8) .05
c
200–499, n (%) 100 (57.8) 170 (50.9) 296 (53.1) 24 (42.1)
> 500, n (%) 54 (31.2) 139 (41.6) 196 (35.2) 28 (49.1)
WHO HIV clinical stage
1o r2 ,n (%) 142 (83.0) 298 (89.8) 487 (87.4) 52 (92.9) .10
c
3o r4 ,n (%) 29 (17.0) 34 (10.2) 70 (12.6) 4 (7.1)
Antiretroviral drug use (%)
Yes, n (%) 142 (82.1) 277 (82.9) 128 (23.0) 4 (7.0) .0001
c
Body mass index, mean (SD)** 23.6 (2.5) 23.7 (2.6) 23.2 (2.4) 23.4 (2.3) .04
p
MUAC in cm, median (range)
U 25.4 (20.0–33.0) 25.2 (20.0–35.0) 24.1 (18.0–36.8) 24.4 (20.6–30.8) .001
§
Socioeconomic status, n (%)
Poor 59 (35.1) 127 (38.5) 230 (41.6) 27 (48.2) .52
c
Middle 69 (41.1) 120 (36.4) 203 (36.7) 19 (33.9)
High 40 (23.8) 83 (25.2) 120 (21.7) 10 (17.9)
Married, n (%)
 157 (90.8) 302 (90.4) 510 (91.7) 47 (82.5) .14
c
NOTE. Abbreviations: HIV, human immunodeﬁciency virus; SP, sulfadoxine-pyrimethamine; TMP-SMX, cotrimoxazole; OR, odds ratio; ANC, Antenatal clinic;
WHO, World Health Organization; SD, standard deviation; MUAC, mid-upper arm circumference.
*Bed net use missing in groups: cotrimoxazole (TMP-SMX): n 5 2; SP-IPTp: n 5 6
**Body mass index missing in groups: TMP-SMX : n 5 2; SP-IPTp: n 5 2
U Mid-upper arm circumference (MUAC) missing in groups: TMP-SMX & SP-IPTp: n 5 1; TMP-SMX: n 5 20; SP-IPTp : n 5 2; None : n 5 1
 Marital status missing in group: None, n 5 1.
§ Kruskal–Wallis test;
cv
2 test;
panalysis of variance test.
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intake and the prevalence of anemia (Table 3).
DISCUSSION
This study was conducted in a sub-Saharan Africa setting
wherein approximately 1 in 5 pregnant women attending an-
tenatal clinics is HIV-infected [28]. During the ﬁrst years of the
study, the Malawi national policy for prevention of malaria in
HIV-infected pregnant women was the use of at least 3 doses of
SP-IPTp and insecticide-treated bed nets (ITNs). Subsequently,
the policy changed to the use of daily TMP-SMX in all HIV-
infected pregnant women in addition to ITNs. Women who
were on daily TMP-SMX prophylaxis were not supposed to
receive SP-IPTp [17]. However, during the period of transition
to this new policy, some women received both SP-IPTp and
TMP-SMX.
Our study found that, after adjusting for important con-
founders, TMP-SMX with or without SP-IPTp was associated
with reduced prevalence of microscopic and PCR-detected
malaria infections and anemia compared with SP-IPTp alone in
HIV-infected pregnant women. To our knowledge, this is the
ﬁrst report demonstrating the superior effectiveness of TMP-
SMX against malaria compared with SP-IPTp in HIV-infected
pregnant women. Our ﬁndings are similar to studies demon-
strating the effectiveness of TMP-SMX in reducing malaria in
children and HIV-infected adults [12–14]. However, a recent
Ugandan study found no difference in the prevalence of pla-
cental malaria between HIV-infected pregnant who took TMP-
SMX and HIV-uninfected pregnant women who took SP-IPTp
[8]. This result is difﬁcult to compare with our ﬁndings because
HIV-infected and uninfected pregnant women used different
drugs. Nevertheless, previous studies have shown that malaria
infection is more frequent and SP-IPT is less efﬁcacious in HIV-
infected than in HIV-uninfected pregnant women [29–32]. In
the Ugandan study, TMP-SMX reduced the risk of malaria in
HIV-infected pregnant women to a level similar to SP-IPT
in HIV-uninfected women [8], which indirectly suggests the
superior efﬁcacy of TMP-SMX in preventing malaria in HIV-
infected pregnant women.
The antimalarial effects of TMP-SMX and SP depend on their
ability to inhibit parasite dihydrofolate reductase (DHFR) and
deoxyhypusine synthase (DHPS), thereby blocking parasite fo-
late synthesis. The setting where this study was conducted has
a high prevalence of triple Asn-108/Ile-51/Arg-59 DHFR and
double Gly-437/Glu-540 DHPS mutations, which reduce the
efﬁcacy of these drugs and has rendered SP ineffective in chil-
dren aged ,5 y [33]. Why was TMP-SMX more effective than
SP? First, this could be because of frequent dosing of TMP-SMX
to the pregnant women compared with SP. TMP-SMX pro-
phylaxis was taken daily which may have resulted in longer
period of malaria protection compared with 2 or 3 doses of
intermittent SP taken during pregnancy. Also, in pregnant
women, treatment doses of SP (1500 mg, stat) given in-
termittently may not achieve adequate blood levels to prevent or
clear malaria infection because of increased bloodelimination of
sulphadoxine and pyrimethamine [34]. Thus, the duration of
effective prevention using SP could be limited because of longer
period of malaria susceptibility compared with that of daily
TMP-SMX. This explanation is partly supported by our obser-
vation of lower prevalence of malaria infection in women who
tookdailyTMP-SMXforalongerdurationcomparedtowomen
who took TMP-SMX for a shorter duration. Some investigators
have even suggested increasing the number of SP doses in HIV-
infected pregnant women not on daily TMP-SMX [35]. Second,
based on in vitro studies, it is possible that there is incomplete
cross-resistance to pyrimethamine and trimethroprim [36], al-
though other studies have found complete cross-resistance [37].
In vivo, some parasites that are resistant to pyrimethamine have
been shown to be sensitive to trimethroprim [38].
Because TMP-SMX and SP are antifolates, intake of both
drugs may increase the risk of anemia because of inhibition of
folate synthesis [39]. TMP-SMX intake during pregnancy has
been associated with increased risk of folate deﬁciency, maternal
anemia, poor birth outcomes [40–43], and neural birth defects
when taken in the ﬁrst trimester [44–46]. However, we found
that TMP-SMX with or without SP-IPTp was associated with
reduced prevalence of maternal anemia and higher hemoglobin
concentration, consistent with beneﬁcial effects in birth out-
comes as reported previously [47].
Our study had several limitations. First, changes in poten-
tial confounding factors such as ITN use, antenatal atten-
dance, and ARV therapy may have occurred parallel to the
change in antimalarial prevention policy, thereby explaining
Figure 1. Prevalence of malaria with 95% confidence interval by
antimalarial drug intake in HIV-infected pregnant women at Thyolo
District Hospital, Malawi (2005–2009).
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attempted to control for these factors in the multivariate
analyses, but because the study was not randomized, there
could still be residual confounding from unmeasured factors.
Because of the cross-sectional design of our study, with only
1-point measurement of both the outcomes and exposure, no
causal inferences can be made from our ﬁndings. Second, our
study may have underestimated the true impact of TMP-SMX
Table 2. Factors associated with malaria infection among HIV-infected pregnant women from Thyolo district Hospital antenatal clinic
in Malawi (2005–2009)
Characteristic
Microscopic Malaria PCR-detected Malaria
n
(% infected)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
U
n
(% infected)
Crude OR
(95% CI)
Adjusted OR
(95% CI)
U
Antimalarial drug
None 57 (14.0) 1.96 (.87–4.41) 1.84 (.76–4.46) 56 (19.6) 1.56 (.77–3.15) 1.39 (.66–2.94)
SP-IPTp 532 (7.7) 1.00 1.00 554 (13.5) 1.00 1.00
Cotrimoxazole 333 (2.7) .33 (.16–.69) .43 (.19–.98) 329 (5.5) .37 (.22–.63) .44 (.25–.78)
SP-IPTp & Cotrimoxazole 171 (.6) .07 (.01–.52) .09 (.01–.66) 168 (3.6) .24 (.10–.55) .24 (.10–.62)
Age, y
> 27 584 (4.1) 1.00 1.00 593 (8.1) 1.00 1.00
,27 529 (7.0) 1.76 (1.04–2.98) 1.27 (.68–2.38) 536 (11.9) 1.54 (1.04–2.28) 1.16 (.73–1.85)
Gravidity
Multigravidae 849 (4.7) 1.00 1.00 861 (8.6) 1.00 1.00
Secundigravidae 194 (8.8) 1.94 (1.08–3.51) 1.75 (.88–3.46) 198 (13.6) 1.68 (1.05–2.69) 1.58 (.93–2.71)
Primigravidae 70 (5.7) 1.23 (.43–3.53) 1.12 (.36–3.52) 70 (15.7) 1.98 (1.00–3.93) 2.00 (.93–4.29)
ANC visits
<3 visits 667 (5.0) 1.00 1.00 675 (8.3) 1.00 1.00
.3 visits 445 (6.3) 1.29 (.7–2.17) .85 (.48–1.53) 451 (12.4) 1.57 (1.06–2.31) 1.20 (.78–1.84)
Any bed net use
Yes 662 (3.02) 1.00 1.00 665 (7.4) 1.00 1.00
No 443 (8.6) 3.01 (1.73–5.25) 2.11 (1.16–3.83) 454 (13.2) 1.91 (1.29–2.85) 1.31 (.85–2.02)
CD4 T cell count cells/lL
> 500 416 (5.8) 1.00 1.00 419 (10.3) 1.00 1.00
200–499 581 (5.3) .92 (.53–1.59) 1.00 (.55–1.81) 591 (10.3) 1.01 (.67–1.52) 1.01 (.65–1.57)
,200 117 (5.1) .88 (.35–2.21) 1.08 (.41–2.82) 118 (7.6) .72 (.34–1.53) .82 (.38–1.77)
WHO HIV clinical stage
3 or 4 134 (1.5) 1.00 * 138 (6.5) 1.00 *
1 or 2 975 (6.0) 4.17 (1.00–17.29) 985 (10.5) 1.67 (.83–3.39)
Antiretroviral drug use
Yes 546 (2.0) 1.00 * 546 (5.3) 1.00 *
No 568 (8.8) 4.70 (2.42–9.12) 582 (14.4) 3.01 (1.94–4.67)
Season of enrollment
Dry 607 (4.0) 1.00 ** 613 (6.2) 1.00 **
Rainy 505 (7.3) 1.92 (1.13–3.26) 513 (14.2) 2.55 (1.69–3.85)
BMI
.24.9 277 (4.7) 1.00 ** 277 (7.6) 1.00 **
18.5–24.9 817 (5.9) 831 (10.9) 1.50 (.91–2.46)
,18.5 16 (.0) 1.27 (.68–2.38) 16 (6.2) .81 (.10–6.46)
Socioeconomic status
High 248 (2.4) 1.00 1.00 247 (6.1) 1.00 1.00
Middle 409 (6.1) 2.63 (1.06–6.49) 2.10 (.82–5.35) 419 (9.6) 1.63 (.88–3.02) 2.16 (1.16–4.00)
Poor 442 (6.8) 2.94 (1.21–7.15) 2.51 (1.00–6.30) 448 (12.3) 2.17 (1.20–3.92) 1.50 (.79–2.83)
NOTE. Abbreviations: PCR, polymerase chain reaction; OR, odds ratio; CI, conﬁdence interval; SP-ITPp, sulfadoxine-pyrimethamine intermittent preventive
therapy during pregnancy; ANC, Antenatal clinic; WHO, World Health Organization; HIV, human immunodeﬁciency virus; BMI, body mass index.
U Adjusted for age, gravidity, number of antenatal visits, bed net use, CD4 cell count, and socioeconomic status.
*Variables not included in the model due to correlation with CD4 count.
**Variable did not meet criteria to be in the model based on directed acylic graph (DAG) analysis for the association between antimalarial drug and malaria
parasitemia [20, 21].
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cause participants were enrolled only in the third trimester of
pregnancy. The study may have missed some malaria in-
fections that occurred in the ﬁrst or second trimester, during
which pregnant women are at an increased risk of malaria
infection [48]. Third, our results potentially may have been
affected by information bias because antimalaria drug expo-
sure was self-reported. Although antenatal records were used
to verify prescription of medications, it was not possible to
conﬁrm compliance of drug intake because no drug levels
were measured. Finally, our study did not evaluate the effects
of TMP-SMX intake with or without SP-IPTp in different
trimesters. This could have allowed better assessment of ef-
fects of TMP-SMX alone or in combination with SP-IPTp on
fetal and maternal toxicity, especially if medication was taken
during the ﬁrst trimester, because simultaneous use of 2 sulfa-
containing drugs is not recommended due to concerns about
potential toxicity. Furthermore, our data were collected dur-
ing the antenatal period only and did not follow up to delivery
to assess the effects of TMP-SMX on birth outcomes such as
placental malaria, low birth weight, and preterm birth de-
liveries. Nevertheless, the differences in malaria parasitemia
among the groups were fairly large (Figure 1), suggesting real
difference in the efﬁcacy of these drugs.
Our study also demonstrated the challenges that resource-
limitedcountriessuchasMalawiencounterwhenchangingdrug
policies. In our retrospective study, some women received an-
timalarial drug regimens that were inconsistent with the newly
introduced drug policy. This was common in settings where
disease-speciﬁc programs such as HIV care services were not
well integrated into the maternal health programs. This resulted
in poor information exchange among staff providing care to the
same client. Drug policy concerning TMP-SMX prophylaxis to
prevent opportunistic infections was not adequately shared with
or understood by antenatal clinic staff providing antenatal
services. This experience shows that to effectively introduce
a public health policy, proper planning and timely training of-
health personnel should always precede implementation, espe-
cially in settings where frequent policy changes do take place.
In conclusion, our study suggests that daily TMP-SMX is
more effective at reducing malaria infections and anemia com-
pared with SP-IPTp alone in HIV-infected pregnant women;
however, the latter treatment was more effective than no anti-
malarial drug.This supports the policy of using dailyTMP-SMX
to prevent malaria in HIV-infected pregnant women instead of
SP-IPTp. The fact that use of both TMP-SMX and SP-IPTp
appeared to be even more efﬁcacious than CTX alone warrants
a randomized-controlled study assessing both the superior ef-
ﬁcacy of the combination therapy and its safety.
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